Suppr超能文献

用于HIV感染暴露后预防的抗逆转录病毒药物的疑似意外及其他不良反应——临床实践五年经验

Suspected unexpected and other adverse reactions to antiretroviral drugs used as post-exposure prophylaxis of HIV infection - five-year experience from clinical practice.

作者信息

Kowalska Justyna D, Pietraszkiewicz Ewa, Firląg-Burkacka Ewa, Horban Andrzej

机构信息

Department for Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.

HIV Out-Patient Clinic, Hospital for Infectious Diseases, Warsaw, Poland.

出版信息

Arch Med Sci. 2018 Apr;14(3):547-553. doi: 10.5114/aoms.2016.59701. Epub 2016 May 5.

Abstract

INTRODUCTION

With increased use of antiretroviral drugs (ARVs) in HIV uninfected persons, proper reporting on suspected unexpected serious adverse reactions (SUSARs) and continued insight into adverse drug reactions (ADRs) are needed for adequate information on safety of ARVs in such populations.

MATERIAL AND METHODS

Medical documentation of persons receiving ARVs after non-occupational HIV exposure (non-occupational post-exposure prophylaxis - nPEP) during 5 successive years (2009-2013) was evaluated by two HIV physicians. Adverse drug reactions s and SUSARs were defined according to international standards. In statistical analyses Cox proportional hazard models were used to identify independent predictors of developing a first ADR.

RESULTS

In total 375 persons received nPEP with the following indications: needle stick (43%), unprotected sexual intercourse (17%), rape (10%) and first aid (10%). In 84 (22%) cases the source patient was HIV positive or an active injecting drug user. In total 170 ADRs were reported. One hundred thirty-nine persons had only 1 ADR. The most frequent first ADRs were gastrointestinal disorders (22%), followed by general symptoms (9%), hypersensitivity reactions (1.6%) and CNS symptoms (1.3%). The remaining events represented less than 1% of all patients. Eight (2.1%) patients developed a SUSAR. In multivariate analyses only age at first visit to the clinic was an independent predictor of developing an ADR (HR = 1.17, 95% CI: 1.03-1.34; = 0.02).

CONCLUSIONS

In our observations ADRs in reaction to nPEP were frequent yet usually mild events, mostly occurring in the first 2 weeks and rarely causing discontinuation. The only significant factor increasing the risk of ADR was age. SUSARs were rare, transient and clinically insignificant.

摘要

引言

随着抗逆转录病毒药物(ARV)在未感染艾滋病毒人群中的使用增加,需要妥善报告疑似意外严重不良反应(SUSAR)并持续深入了解药物不良反应(ADR),以便充分掌握此类人群中ARV的安全性信息。

材料与方法

由两名艾滋病医生对连续五年(2009 - 2013年)接受非职业性艾滋病毒暴露后抗逆转录病毒药物治疗(非职业性暴露后预防 - nPEP)的患者的医疗记录进行评估。药物不良反应和SUSAR根据国际标准进行定义。在统计分析中,使用Cox比例风险模型来确定首次发生ADR的独立预测因素。

结果

共有375人接受nPEP治疗,其指征如下:针刺伤(43%)、无保护性行为(17%)、强奸(10%)和急救(10%)。在84例(22%)病例中,源患者为艾滋病毒阳性或活跃的注射吸毒者。共报告了170例ADR。139人仅发生1例ADR。最常见的首次ADR为胃肠道疾病(22%),其次是全身症状(9%)、过敏反应(1.6%)和中枢神经系统症状(1.3%)。其余事件在所有患者中所占比例不到1%。8例(2.1%)患者发生了SUSAR。在多变量分析中,仅首次到诊所就诊时的年龄是发生ADR的独立预测因素(HR = 1.17,95%CI:1.03 - 1.34;P = 0.02)。

结论

在我们的观察中,nPEP引起的ADR很常见,但通常为轻度事件,大多发生在最初2周内,很少导致停药。增加ADR风险的唯一显著因素是年龄。SUSAR很少见,是短暂性的,且在临床上无显著意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/486c/5949906/5c132eb1cd62/AMS-14-27490-g001.jpg

相似文献

2
The suspected unexpected and serious adverse events of antiretroviral drugs used as HIV prophylaxis in HIV uninfected persons.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19733. doi: 10.7448/IAS.17.4.19733. eCollection 2014.
4
Monitoring drug safety in Astrakhan, Russia.
Int J Risk Saf Med. 2015;27 Suppl 1:S33-4. doi: 10.3233/JRS-150680.
5
Adverse Drug Reactions to Antiretroviral Therapy in HIV-Infected Patients at the Largest Public Hospital in Nicaragua.
J Int Assoc Provid AIDS Care. 2014 Sep-Oct;13(5):466-70. doi: 10.1177/2325957414535978. Epub 2014 Jun 16.
9
A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues.
Eur J Clin Pharmacol. 2021 Nov;77(11):1697-1704. doi: 10.1007/s00228-021-03134-9. Epub 2021 Jun 18.

本文引用的文献

3
Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis.
AIDS. 2014 Nov 28;28(18):2721-7. doi: 10.1097/QAD.0000000000000505.
4
Safety, tolerability and effectiveness of HIV non-occupational prophylaxis in Taiwan.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19736. doi: 10.7448/IAS.17.4.19736. eCollection 2014.
5
The suspected unexpected and serious adverse events of antiretroviral drugs used as HIV prophylaxis in HIV uninfected persons.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19733. doi: 10.7448/IAS.17.4.19733. eCollection 2014.
6
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):324-31. doi: 10.1097/QAI.0000000000000158.
7
Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington.
PLoS One. 2014 Aug 20;9(8):e105030. doi: 10.1371/journal.pone.0105030. eCollection 2014.
9
HIV post exposure prophylaxis induced bicytopenia: a case report.
AIDS Res Ther. 2014 Feb 7;11(1):11. doi: 10.1186/1742-6405-11-11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验